Notice of Results

RNS Number : 7859G

Hikma Pharmaceuticals Plc

10 August 2016

 

Notice of Results

LONDON, UK, 10 August, 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing pharmaceuticals company, will announce its interim financial results for the six months ended 30 June 2016 on Wednesday 24 August 2016.

A presentation and webcast for analysts will be held at 9.30am BST at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.

To join via conference call please dial: [phone]

UK Toll Free Number: 0808 109 0700

The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://cache.merchantcantos.com/webcast/webcaster/4000/7464/16532/63539/Lobby/default.htm 

Playback facility:

A playback of the conference call will be available up to 7 days after the presentation.

UK & International Number: [phone]

UK Toll-Free Number: 0800 633 8453

Replay PIN code: 8050955#

-Ends-

Enquiries

Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations	[phone]/[phone]
Lucinda Baker, Deputy Director of Investor Relations	[phone]/[phone]
Zeena Murad, Investor Relations Manager	[phone]/[phone]
FTI Consulting
Ben Atwell/Matthew Cole	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million. 

 

END

 

 

NORZMGMRRGGGVZG